Deracoxib | CAS#169590-41-4 | NSAID inhibitor | COX-2 inhibitor

MedKoo Cat#: 540103 | Name: Deracoxib

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deracoxib is an NSAID and COX-2 inhibitor used to treat osteoarthritis. It induces cell cycle arrest and apoptosis in mammary tumor cells, decreases platelet aggregation, and lowers inflammatory responses.

Chemical Structure

Deracoxib

CAS#169590-41-4

Theoretical Analysis

MedKoo Cat#: 540103

Name: Deracoxib

CAS#: 169590-41-4

Chemical Formula: C17H14F3N3O3S

Exact Mass: 397.0708

Molecular Weight: 397.37

Elemental Analysis: C, 51.38; H, 3.55; F, 14.34; N, 10.57; O, 12.08; S, 8.07

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 350.00	2 Weeks
100mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Deracoxib; Deramaxx; deracoxibum; Deram; SC 046; SC046; SC-046; SC-46; SC46; SC 46; SC-59046; SC59046; SC 59046

IUPAC/Chemical Name

4-(3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide

InChi Key

WAZQAZKAZLXFMK-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)

SMILES Code

O=S(C1=CC=C(N2N=C(C(F)F)C=C2C3=CC=C(OC)C(F)=C3)C=C1)(N)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).

In vitro activity:

The aim of this study was to determine the direct antiproliferative effects of nonsteroidal anti-inflammatory drugs (NSAIDs), piroxicam and deracoxib, at a variety of concentrations as both single and combined treatments on canine mammary carcinoma cell line CMT-U27 and to understand the mechanisms of cell death. fter 72 h incubation, significant reductions were seen at 250, 500, and 1000 μM doses of deracoxib by 16.49%, 16.64%, and 40.69% of the control level, respectively. The apoptotic cell number of CMTU27 cells after 72 h incubation in the presence or absence of piroxicam and deracoxib at various concentrations (50–1000 μM) was shown in Figure 3. Deracoxib at 250 μM, and higher concentrations (P < 0.01, P < 0.001) decreased the number of viable cells and increased the number of apoptotic cells as a sum of early and late apoptotic cells significantly. Reference: ScientificWorldJournal. 2012;2012:976740. https://pubmed.ncbi.nlm.nih.gov/23251109/

In vivo activity:

The objective of this study was to evaluate the antitumor activity and toxic effects of deracoxib, a selective cyclooxygenase-2 inhibitor, in dogs with transitional cell carcinoma (TCC) of the urinary bladder. Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. f 24 dogs for which tumor response was assessed, 4 (17%) had partial remission, 17 (71%) had stable disease, and 3 (13%) had progressive disease; initial response could not be assessed in 2 of 26 dogs. The median survival time was 323 days. Median time to progressive disease was 133 days. Renal, hepatic, and gastrointestinal abnormalities attributed to deracoxib administration were noted in 4% (1/26), 4% (1/26), and 19% (5/26) of dogs, respectively. These results indicated that deracoxib was generally well tolerated by dogs and had antitumor activity against TCC. Reference: J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. https://pubmed.ncbi.nlm.nih.gov/21985349/

	Solvent	mg/mL	mM
Solubility
	DMSO	65.0	163.58

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 397.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ustün Alkan F, Ustüner O, Bakırel T, Cınar S, Erten G, Deniz G. The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal. 2012;2012:976740. doi: 10.1100/2012/976740. Epub 2012 Nov 7. PMID: 23251109; PMCID: PMC3518048. 2. Royals SR, Farese JP, Milner RJ, Lee-Ambrose L, van Gilder J. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res. 2005 Nov;66(11):1961-7. doi: 10.2460/ajvr.2005.66.1961. PMID: 16334957. 3. Bienhoff SE, Smith ES, Roycroft LM, Roberts ES. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg. 2012 Apr;41(3):336-44. doi: 10.1111/j.1532-950X.2011.00942.x. Epub 2012 Jan 6. PMID: 22225463. 4. McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. doi: 10.2460/javma.239.8.1084. PMID: 21985349.

In vitro protocol:

In vivo protocol:

1. Bienhoff SE, Smith ES, Roycroft LM, Roberts ES. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg. 2012 Apr;41(3):336-44. doi: 10.1111/j.1532-950X.2011.00942.x. Epub 2012 Jan 6. PMID: 22225463. 2. McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. doi: 10.2460/javma.239.8.1084. PMID: 21985349.

1: Bienhoff SE, Smith ES, Roycroft LM, Roberts ES, Baker LD. Efficacy and safety of deracoxib for the control of postoperative pain and inflammation associated with dental surgery in dogs. ISRN Vet Sci. 2012 Jan 23;2011:593015. doi: 10.5402/2011/593015. Print 2011. PubMed PMID: 23738113; PubMed Central PMCID: PMC3658545. 2: Ustün Alkan F, Ustüner O, Bakırel T, Cınar S, Erten G, Deniz G. The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal. 2012;2012:976740. doi: 10.1100/2012/976740. Epub 2012 Nov 7. PubMed PMID: 23251109; PubMed Central PMCID: PMC3518048. 3: McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. doi: 10.2460/javma.239.8.1084. PubMed PMID: 21985349. 4: Kahn SA, Mullin CM, de Lorimier LP, Burgess KE, Risbon RE, Fred RM 3rd, Drobatz K, Clifford CA. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. Can Vet J. 2013 Mar;54(3):237-42. PubMed PMID: 23997259; PubMed Central PMCID: PMC3573628. 5: Davis JL, Marshall JF, Papich MG, Blikslager AT, Campbell NB. The pharmacokinetics and in vitro cyclooxygenase selectivity of deracoxib in horses. J Vet Pharmacol Ther. 2011 Feb;34(1):12-6. doi: 10.1111/j.1365-2885.2010.01185.x. PubMed PMID: 21219338. 6: Bienhoff SE, Smith ES, Roycroft LM, Roberts ES. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg. 2012 Apr;41(3):336-44. doi: 10.1111/j.1532-950X.2011.00942.x. Epub 2012 Jan 6. PubMed PMID: 22225463. 7: Mullins KB, Thomason JM, Lunsford KV, Pinchuk LM, Langston VC, Wills RW, McLaughlin RM, Mackin AJ. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. Vet Anaesth Analg. 2012 Mar;39(2):206-17. doi: 10.1111/j.1467-2995.2011.00684.x. Epub 2012 Jan 17. PubMed PMID: 22248445. 8: Ustün Alkan F, Bakirel T, Ustüner O, Yardibi H. In vitro effects of doxorubicin and deracoxib on oxidative-stress-related parameters in canine mammary carcinoma cells. Acta Vet Hung. 2014 Sep;62(3):372-85. doi: 10.1556/AVet.2014.012. PubMed PMID: 25038953. 9: Case JB, Fick JL, Rooney MB. Proximal duodenal perforation in three dogs following deracoxib administration. J Am Anim Hosp Assoc. 2010 Jul-Aug;46(4):255-8. PubMed PMID: 20610698. 10: Blois SL, Allen DG, Wood RD, Conlon PD. Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res. 2010 Mar;71(3):349-58. doi: 10.2460/ajvr.71.3.349. PubMed PMID: 20187838. 11: Royals SR, Farese JP, Milner RJ, Lee-Ambrose L, van Gilder J. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res. 2005 Nov;66(11):1961-7. PubMed PMID: 16334957. 12: Bakirel T, Alkan FÜ, Üstüner O, Çinar S, Yildirim F, Erten G, Bakirel U. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27. J Vet Med Sci. 2016 May 3;78(4):657-68. doi: 10.1292/jvms.15-0387. Epub 2016 Jan 29. PubMed PMID: 26822118; PubMed Central PMCID: PMC4873858. 13: Gordon-Evans WJ, Dunning D, Johnson AL, Knap KE. Randomised controlled clinical trial for the use of deracoxib during intense rehabilitation exercises after tibial plateau levelling osteotomy. Vet Comp Orthop Traumatol. 2010;23(5):332-5. doi: 10.3415/VCOT-09-11-0121. Epub 2010 Aug 25. PubMed PMID: 20740263. 14: Tomlinson JE, Blikslager AT. Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum. Equine Vet J. 2005 Jan;37(1):75-80. PubMed PMID: 15651739. 15: Roberts ES, Van Lare KA, Marable BR, Salminen WF. Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. J Vet Pharmacol Ther. 2009 Aug;32(4):329-37. doi: 10.1111/j.1365-2885.2008.01043.x. PubMed PMID: 19614837. 16: Millis DL, Weigel JP, Moyers T, Buonomo FC. Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet Ther. 2002 Winter;3(4):453-64. PubMed PMID: 12584683. 17: Panciera DL, Refsal KR, Sennello KA, Ward DL. Effects of deracoxib and aspirin on serum concentrations of thyroxine, 3,5,3'-triiodothyronine, free thyroxine, and thyroid-stimulating hormone in healthy dogs. Am J Vet Res. 2006 Apr;67(4):599-603. PubMed PMID: 16579752. 18: Wiwanitkit V. Use of deracoxib during intense rehabilitation exercises. Vet Comp Orthop Traumatol. 2010;23(6):472. PubMed PMID: 21155163. 19: Karnik PS, Johnston S, Ward D, Broadstone R, Inzana K. The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model. Vet Surg. 2006 Jan;35(1):34-42. PubMed PMID: 16409407. 20: Gassel AD, Tobias KM, Cox SK. Disposition of deracoxib in cats after oral administration. J Am Anim Hosp Assoc. 2006 May-Jun;42(3):212-7. PubMed PMID: 16611933.

View History

Resorufin-R1

MedKoo CAT#: 463559

CAS#: unknown